A 21% prostate cancer (PCa) mortality reduction was observed in the European Randomized Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. A direct correlation between stage shift and changes in PCa-mortality would support earlier detection through screening as the main reason for this reduction. In this study we empirically estimate how changes in the risk of being diagnosed with (advanced) PCa are related to the changes in PCa death in the ERSPC using a meta-regression approach. In total 81% and 89% of the changes in PCa mortality could be explained by changes in PCa incidence. Although this analysis cannot show direct causal relations, results support the hypothesis that PSA screening reduced PCa mortality by detecting cancer at an earlier stage while still curable. These findings do however not open the way to unrestricted PSA based screening for PCa. A balance between harm and benefit needs to be found. This article is protected by copyright. All rights reserved.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
BJU international. 2016 Apr 22 [Epub ahead of print]
Leonard P Bokhorst, Marco Zappa, Sigrid V Carlsson, Maciej Kwiatkowski, Louis Denis, Alvaro Paez, Jonas Hugosson, Sue Moss, Anssi Auvinen, Monique J Roobol
Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands., Unit of Clinical and Descriptive Epidemiology ISPO, Florence, Italy., Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, USA" and "Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden., Department of Urology, Kantonsspital Aarau, Aarau, Switzerland., Oncology Centre Antwerp, Antwerp, Belgium., Department of Urology, Hospital Universitario de Fuenlabrada, Madrid, Spain., Department of Urology, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden., Centre for Cancer Prevention, Queen Mary University of London, London, UK., School of Health Sciences, University of Tampere, Tampere, Finland., Department of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands.